摘要
目的探究晚期复发性卵巢癌患者化疗期间加用白蛋白结合型紫杉醇(nab-paclitaxel,Nab-p)的效果及影响总生存期(overall survival,OS)的主要因素。方法选取2019年7月至2022年12月赣州市人民医院接收的68例晚期复发性卵巢癌患者作为研究对象,按照治疗方式不同分为观察组与对照组,各34例。观察组采用Nab-p结合卡铂治疗,对照组采用紫杉醇结合卡铂治疗,比较两组近期疗效、血清肿瘤标志物水平、不良反应发生率、生命质量评分,分析影响复发性卵巢癌患者OS的影响因素。结果观察组治疗总有效率为85.29%,高于对照组的61.76%,差异有统计学意义(P<0.05);治疗后,两组糖类抗原125(carbohydrate antigen 125,CA125)、癌胚抗原(carcino-embryonic antigen,CEA)、人附睾蛋白4(human epididymis protein 4,HE4)水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);观察组不良反应发生率为8.82%,低于对照组的32.35%,差异有统计学意义(P<0.05);观察组生理、心理、社会、环境、总体生命质量评分均高于对照组,差异有统计学意义(P<0.05);多因素Logistic分析结果显示,Nab-p结合卡铂、合并腹水、CA125升高是影响复发性卵巢癌患者OS的独立危险因素(P<0.05)。结论Nab-p能显著提高晚期复发性卵巢癌化疗患者的生命质量,临床应密切关注CA125升高合并腹水患者,选择最佳治疗方案,以改善预后。
Objective To explore the effect of adding nab-paclitaxel(Nab-p)during chemotherapy in patients with advanced recurrent ovarian cancer and the main factors affecting overall survival(OS).Methods A total of 68 patients with advanced recurrent ovarian cancer admitted to Ganzhou People's Hospital from July 2019 to December 2022 were selected as the research subjects and they divided into the observation group and the control group according to different treatment methods,with 34 cases in each group.The observation group was treated with Nab-p combined with carboplatin,while the control group was treated with paclitaxel combined with carboplatin.The short-term efficacy,serum tumor marker levels,incidence of adverse reactions,and quality of life scores were compared between the two groups,and the influencing factors affecting OS in patients with recurrent ovarian cancer were analyzed.Results The total effective rate in treatment in the observation group was 85.29%,which was higher than 61.76%in the control group,and the difference was statistically significant(P<0.05).After treatment,the levels of carbohydrate antigen 125(CA125),carcino-embryonic antigen(CEA)and human epididymis protein 4(HE4)of the two groups were lower than those before treatment,and the observation group was lower than the control group,the differences were statistically significant(P<0.05).The incidence of adverse reactions in the observation group was 8.82%,which was lower than 32.35%in the control group,the difference was statistically significant(P<0.05).The scores of physiology,psychology,society,environment and overall quality of life in the observation group were higher than those in the control group,and the differences were statistically significant(P<0.05).Multivariate Logistic analysis showed that Nab-p combined with carboplatin,ascites and elevated CA125 were independent risk factors for OS in patients with recurrent ovarian cancer(P<0.05).Conclusion Nab-p can significantly improve the quality of life of patients with advanced recurrent ovarian cancer undergoing chemotherapy,clinically,we should pay close attention to patients with elevated CA125 and ascites,and choose the best treatment scheme to improve the prognosis.
作者
温时来
李廷
张学兵
蓝素珍
WEN Shilai;LI Ting;ZHANG Xuebing;LAN Suzhen(Department of Oncology,Ganzhou People's Hospital,Ganzhou,Jiangxi,341000,China)
出处
《当代医学》
2025年第8期61-65,共5页
Contemporary Medicine
关键词
复发性卵巢癌
晚期
化疗
白蛋白结合型紫杉醇
生命质量
总生存期
相关因素
Recurrent ovarian cancer
Late stage
Chemotherapy
Nab-paclitaxel paclitaxel
Quality of life
Over-all survival
Correlative factor
